Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results

Cyclacel Pharmaceuticals (NASDAQ:CYCC) a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, today reported its financial results and business highlights for the fourth quarter and full year ended December 31, 2017.  The Company’s net loss applicable to common shareholders for the three months and year ended December 31, 2017 was $2.1 million and $14.9 million, respectively.  As of December 31, 2017, cash and cash equivalents totaled $23.9 million.

As quoted in the press release:

Discussions with principal investigators and/or cooperative groups progressed with the objective of evaluating CYC065 in both pediatric and adult patients with solid tumors.  The Company is discussing with an investigator cooperative group a potential evaluation of CYC065 in patients with neuroblastoma, a mostly pediatric, life-threatening malignancy, frequently associated with MYCN amplification.

Click here to read the full press release.